<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139468">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01799382</url>
  </required_header>
  <id_info>
    <org_study_id>13001-Trisolini</org_study_id>
    <nct_id>NCT01799382</nct_id>
  </id_info>
  <brief_title>Role of Rapid On-site Evaluation for Mutational Analysis of EBUS-TBNA Specimens</brief_title>
  <official_title>Mutational Analysis of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) Specimens in Patients With Advanced Non-small Cell Lung Cancer: a Randomized Trial of Rapid On-site Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maggiore Bellaria Hospital, Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maggiore Bellaria Hospital, Bologna</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if rapid on-site evaluation of EBUS-TBNA samples
      can increase the percentage of patients with advanced non-squamous non-small cell lung
      cancer in whom both pathologic subtyping and mutational analysis are obtained.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Mutational analysis of epidermal growth factor receptor (EGFR), K-ras, and ALK (anaplastic lymphoma kinase) genes</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients for whom the mutational analysis of epidermal growth factor receptor (EGFR), K-ras, and ALK (anaplastic lymphoma kinase) genes on EBUS-TBNA samples is obtained</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic yield of EBUS-TBNA</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequacy of EBUS-TBNA samples</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>EBUS-TBNA + Rapid on-site evaluation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will undergo rapid-on site evaluation of samples obtained with EBUS-TBNA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBUS-TBNA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will undergo EBUS-TBNA without rapid on-site evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rapid on-site evaluation</intervention_name>
    <description>Rapid on-site evaluation consists on the cytological evaluation of samples obtained during a diagnostic procedure by a pathologist present in the diagnostic suite. In the present study, cytological samples obtained with EBUS-TBNA during bronchoscopy will be evaluated.</description>
    <arm_group_label>EBUS-TBNA + Rapid on-site evaluation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EBUS-TBNA</intervention_name>
    <description>EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy</description>
    <arm_group_label>EBUS-TBNA + Rapid on-site evaluation</arm_group_label>
    <arm_group_label>EBUS-TBNA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Suspected hilar or mediastinal lymph node metastasis from lung cancer

        Exclusion Criteria:

          -  Pregnancy

          -  Uncontrolled coagulopathy

          -  Refusal to sign informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rocco Trisolini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maggiore Hospital, Bologna, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rocco Trisolini, MD</last_name>
    <phone>0039-347-4251647</phone>
    <email>rocco.trisolini@ausl.bologna.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maggiore Hospital</name>
      <address>
        <city>Bologna</city>
        <state>Emilia Romagna</state>
        <zip>40133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rocco Trisolini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco Patelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandra Cancellieri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 27, 2013</lastchanged_date>
  <firstreceived_date>February 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maggiore Bellaria Hospital, Bologna</investigator_affiliation>
    <investigator_full_name>Rocco Trisolini</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
